Efficacy and Safety of Secukinumab in Psoriasis: Five-year Real Life Experience

Overview

Journal An Bras Dermatol

Specialty Dermatology

Date 2024 Jul 19

PMID 39030105

Authors

Ersoy Acer

Hilal Kaya Erdogan

Esra Agaoglu

Hatice Basturk

Muzaffer Bilgin

Zeynep Nurhan Saracoglu

Affiliations

Soon will be listed here.

Abstract

Background: The efficacy and safety of secukinumab in psoriasis patients has been demonstrated in randomized controlled clinical trials.

Objectives: The authors aimed to evaluate the efficacy and safety of secukinumab in plaque psoriasis patients followed in our clinic.

Methods: Data from 101 plaque psoriasis patients who received at least 16 weeks of secukinumab treatment between June 2018 and June 2023 were retrospectively analyzed.

Results: Fifty-three (53%) of the patients were bionaive. PASI-75, -90, -100 response rates were 72%, 50%, 30% respectively at week 16 in all patients. PASI-75 and -90 responses were higher in naive patients at weeks 16 and 28 (p < 0.001, p < 0.001, p < 0.01, p = 0.01, respectively). The percentage of patients with PASI ≤ 1, ≤ 3, ≤ 5 were 50%, 77%, and 92%, respectively at week 16. They were higher in the naive group than in nonnaive group at weeks 16 and 28 (p = 0.02, p < 0.01, p = 0.05, p = 0.07, p < 0.01, p = 0.03, respectively). At week 52, PASI-75, -90, -100 responses were significantly lower in smoking patients (p = 0.04, p = 0.03, p < 0.01, respectively). The mean duration of secukinumab treatment was 19.80 ± 12.76 months. Secukinumab was discontinued 14 (26.4%) naive patients and 28 (58.3%) nonnaive patients at one occasion during treatment (p < 0.001). The most common adverse event in patients was mucocutaneous candida infection (8%). No hepatitis B or C reactivation and no active or reactivation tuberculosis were observed in any of the patients during the follow-up period.

Study Limitations: This is a single-center retrospective study with relatively few patients including only the Turkish population.

Conclusion: Secukinumab seems to be effective in plaque psoriasis, particularly in bionaive and non-smokers. Moreover, it is safe in patients with inactive hepatitis or tuberculosis.

References

Ergun T, Seckin D, Demir G, Direskeneli H . Secukinumab and infectious adverse effects: A real-life experience of 63 psoriasis patients. Australas J Dermatol. 2021; 62(3):e423-e426. DOI: 10.1111/ajd.13588. View

Diotallevi F, Gambini D, Radi G, Simonetti O, Offidani A . Should we be concerned about gastrointestinal-related adverse events in patients with plaque psoriasis receiving secukinumab therapy? A retrospective, real-life study. Dermatol Ther. 2022; 35(11):e15794. PMC: 9786729. DOI: 10.1111/dth.15794. View

Lebwohl M, Deodhar A, Griffiths C, Menter M, Poddubnyy D, Bao W . The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up. Br J Dermatol. 2021; 185(5):935-944. DOI: 10.1111/bjd.20136. View

Schreiber S, Colombel J, Feagan B, Reich K, Deodhar A, McInnes I . Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. Ann Rheum Dis. 2019; 78(4):473-479. PMC: 6530077. DOI: 10.1136/annrheumdis-2018-214273. View

Wu J, Kavanaugh A, Lebwohl M, Gniadecki R, Merola J . Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2022; 36(6):797-806. PMC: 9313585. DOI: 10.1111/jdv.18044. View

Takeshita J, Grewal S, Langan S, Mehta N, Ogdie A, Van Voorhees A . Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol. 2017; 76(3):377-390. PMC: 5731650. DOI: 10.1016/j.jaad.2016.07.064. View

Chiricozzi A, Balato A, Conrad C, Conti A, Dapavo P, Ferreira P . Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study. J Dermatolog Treat. 2019; 31(5):476-483. DOI: 10.1080/09546634.2019.1671577. View

Armstrong A, Read C . Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA. 2020; 323(19):1945-1960. DOI: 10.1001/jama.2020.4006. View

Galluzzo M, DAdamio S, Silvaggio D, Lombardo P, Bianchi L, Talamonti M . In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis. Expert Opin Biol Ther. 2019; 20(2):173-182. DOI: 10.1080/14712598.2020.1708897. View

10.

Hawkes J, Chan T, Krueger J . Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017; 140(3):645-653. PMC: 5600287. DOI: 10.1016/j.jaci.2017.07.004. View

11.

Langley R, Elewski B, Lebwohl M, Reich K, Griffiths C, Papp K . Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med. 2014; 371(4):326-38. DOI: 10.1056/NEJMoa1314258. View

12.

Pinter A, Gerdes S, Papavassilis C, Reinhardt M . Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis. J Dermatolog Treat. 2019; 31(8):769-775. DOI: 10.1080/09546634.2019.1626973. View

13.

Blauvelt A, Prinz J, Gottlieb A, Kingo K, Sofen H, Ruer-Mulard M . Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2014; 172(2):484-93. DOI: 10.1111/bjd.13348. View

14.

Bu J, Ding R, Zhou L, Chen X, Shen E . Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review. Front Immunol. 2022; 13:880201. PMC: 9226890. DOI: 10.3389/fimmu.2022.880201. View

15.

Ortiz-Salvador J, Saneleuterio-Temporal M, Magdaleno-Tapial J, Velasco-Pastor M, Pujol-Marco C, Sahuquillo-Torralba A . A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients. J Am Acad Dermatol. 2019; 81(2):427-432. DOI: 10.1016/j.jaad.2019.02.062. View

16.

Notario J, Deza G, Vilarrasa E, Valenti F, Munoz C, Mollet J . Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain. J Dermatolog Treat. 2018; 30(5):424-429. DOI: 10.1080/09546634.2018.1528000. View

17.

Sanford M, McKeage K . Secukinumab: first global approval. Drugs. 2015; 75(3):329-38. DOI: 10.1007/s40265-015-0359-0. View

18.

Musumeci M, Nasca M, Boscaglia S, Micali G . The role of lifestyle and nutrition in psoriasis: Current status of knowledge and interventions. Dermatol Ther. 2022; 35(9):e15685. PMC: 9541512. DOI: 10.1111/dth.15685. View

19.

Elewski B, Baddley J, Deodhar A, Magrey M, Rich P, Soriano E . Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis. JAMA Dermatol. 2020; 157(1):43-51. PMC: 7527940. DOI: 10.1001/jamadermatol.2020.3257. View

20.

Augustin M, Jullien D, Martin A, Peralta C . Real-world evidence of secukinumab in psoriasis treatment - a meta-analysis of 43 studies. J Eur Acad Dermatol Venereol. 2020; 34(6):1174-1185. DOI: 10.1111/jdv.16180. View